secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001564590-22-003608
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate
------------------------------------------------------------------------

- Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.
- Revenue rose to $27.4M from $21.3M, primarily from license and collaboration revenue.
- R&D expense nearly doubled to $65.8M; G&A expense tripled to $25.0M.
- Initiated PALISADE Phase 3 study for ARO-APOC3 in familial chylomicronemia syndrome.
- Entered exclusive license with GSK for ARO-HSD (NASH); advanced two pulmonary candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/0001564590-22-003608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/arwr-8k_20220202.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-003608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer